The main objective of the study is to analyse the role of a neurotrophic factor (BDNF) as a putative biological marker of the cognitive recovery in schizophrenia following a Cognitive Remediation Therapy (CRT). Additionally, the role as outcome predictors of BDNF serum levels and the Val66met polymorphism and data from functional and structural neuroimaging will be studied.
Name: Cognitive Remediation Therapy
Name: Psychoeducation
Description: Change Measurements of serum BDNF levels will be carried out by personnel blind to subjects' group assignment. Platelet and serum samples will be diluted with diluent included in the R&D Human BDNF Quantikine Enzym Linked Immunosorbent Assay (ELISA) kit (Yasuhito et al. 1987).
Measure: BDNF (change from baseline serum BDNF levels) Time: Baseline, 1 month and 4 monthsDescription: Change from baseline in Positive and Negative Syndrome Scale (PANSS) scores at time 16 weeks
Measure: Symptoms (Change from baseline in Positive and Negative Syndrome Scale (PANSS) scores) Time: Baseline and 4 monthsAllocation: Randomized
Parallel Assignment
There is one SNP
Additionally, the role as outcome predictors of BDNF serum levels and the Val66met polymorphism and data from functional and structural neuroimaging will be studied. --- Val66met ---